Loading…
IGC Pharma, Inc. is projected to rise to $0.3036 by 2027, a +24% move from its current price of $0.2451. IGC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2396 | $0.2452 | $0.2509 | +0.03% |
| Aug 6 | $0.2374 | $0.2453 | $0.2534 | +0.06% |
| Aug 7 | $0.2357 | $0.2453 | $0.2554 | +0.10% |
| Aug 8 | $0.2343 | $0.2454 | $0.2571 | +0.13% |
| Aug 9 | $0.2331 | $0.2455 | $0.2585 | +0.16% |
| Aug 10 | $0.232 | $0.2456 | $0.2599 | +0.19% |
| Aug 11 | $0.2311 | $0.2457 | $0.2612 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2311 | $0.2457 | $0.2612 | +0.23% |
| Week 2 | $0.2258 | $0.2462 | $0.2685 | +0.45% |
| Week 3 | $0.2219 | $0.2468 | $0.2744 | +0.68% |
| Week 4 | $0.2188 | $0.2473 | $0.2796 | +0.91% |
| Week 5 | $0.2162 | $0.2479 | $0.2843 | +1.14% |
| Week 6 | $0.2138 | $0.2485 | $0.2887 | +1.37% |
| Week 7 | $0.2118 | $0.249 | $0.2928 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IGC Pharma, Inc. is a clinical stage pharmaceutical company focused on neuropsychiatric and neurodegenerative disorders, with a primary emphasis on Alzheimer's disease in the United States and Colombia. Its lead product is IGC-AD1, which is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
The company has pre-clinical stage candidates including TGR-63 and IGC-M3 to treat Alzheimer's disease, and it also develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc.
in March 2023. IGC Pharma was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma operates in the Healthcare sector, pursuing therapies for Alzheimer's disease and related conditions, while expanding into AI-enabled tools for medical providers. These elements frame its clinical and product strategy as a clinical stage pharmaceutical company with a focus on neuroscience and patient care solutions at the intersection of medicine and technology.
The stock trades at $0.24 per share and has a market capitalization of $25.05M. Its rank is 4792.
Technical indicators show NEUTRAL sentiment, RSI14 at 20, SMA50 at $0.2768, and SMA200 at $0.3034, with a near-term support at $0.24 and resistance at $0.28. The 30-day price range runs from $0.2063 to $0.2792, and annualized volatility is 40%.
Near-term forecast for 2026 presents min $0.24, avg $0.24, max $0.3022 with ROI 0 and sentiment NEUTRAL.
A major floor 11.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.1% away) — a key level to hold.
The nearest ceiling, 14.2% above — a clean break opens room to run.
A major ceiling 42.8% above — clearing it would confirm fresh momentum.
Key IGC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IGC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.252 | Sell | $0.2523 | Sell |
| MA 10 | $0.26 | Sell | $0.2571 | Sell |
| MA 20 | $0.266 | Sell | $0.263 | Sell |
| MA 50 | $0.2754 | Sell | $0.2735 | Sell |
| MA 100 | $0.2861 | Sell | $0.2835 | Sell |
| MA 200 | $0.302 | Sell | $0.2991 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.47 | Neutral |
| Stoch RSI (14) | 54.75 | Neutral |
| CCI (20) | -121.21 | Sell |
| Williams %R (14) | -66.67 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -7.41 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 33.33 | Neutral |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 29.52 | Buy |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.24 | Buy |
| ADX (14) | 22.39 | Sell |
| ATR (14) | 0.00 | Info |
Near-term picture shows NEUTRAL sentiment with RSI14 at 20.
SMA50 is $0.2768 and SMA200 is $0.3034, with current price near the support level at $0.24 and facing resistance at $0.28.
The 30-day range is $0.2063 to $0.2792, indicating limited near-term movement within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.24 | $0.2451 | $0.307 | 0% | Neutral | |
| $0.2455 | $0.3036 | $0.3947 | +24% | Bullish | |
| $0.2623 | $0.3321 | $0.4462 | +36% | Bullish | |
| $0.28 | $0.3614 | $0.498 | +47% | Bullish | |
| $0.2766 | $0.3632 | $0.5113 | +48% | Bullish | |
| $0.2779 | $0.3706 | $0.5316 | +51% | Bullish | |
| $0.3002 | $0.4061 | $0.5925 | +66% | Bullish | |
| $0.3188 | $0.4371 | $0.6474 | +78% | Bullish | |
| $0.3659 | $0.508 | $0.7631 | +107% | Bullish | |
| $0.3993 | $0.5611 | $0.8541 | +129% | Bullish | |
| $0.4996 | $0.7413 | $1.19 | +202% | Bullish | |
| $0.8273 | $1.35 | $2.35 | +449% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.24 | $0.2451 | $0.293 | +0.00% |
| September 2026 | $0.2146 | $0.2527 | $0.3049 | +3.09% |
| October 2026 | $0.2132 | $0.2525 | $0.3075 | -0.08% |
| November 2026 | $0.2065 | $0.2457 | $0.3015 | -2.68% |
| December 2026 | $0.208 | $0.2485 | $0.307 | +1.14% |
Click any year to see its month-by-month IGC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IGC could reach as high as $0.307, with a base case around $0.2451 and support toward $0.24 — roughly 0% from $0.2451. Price action looks broadly range-bound.
Expect IGC to range from $0.2455 to $0.3947 through 2027. The $0.3036 average target implies a +24% move from current prices. That is up +24% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IGC price prediction for 2028 points to an average of $0.3321 (low $0.2623, high $0.4462) — a potential gain of +36% on today's $0.2451. Momentum favours further upside here.
In 2029, IGC is projected to trade between $0.28 and $0.498, averaging $0.3614 — a potential gain of +47% from today's $0.2451. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
IGC Pharma, Inc.'s 2030 outlook centres on $0.3632, within a $0.2766 to $0.5113 range. That is up 0% on the projected 2029 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2031, IGC could reach as high as $0.5316, with a base case around $0.3706 and support toward $0.2779 — roughly +51% from $0.2451. Buyers look set to stay in control over this stretch.
Expect IGC to range from $0.3002 to $0.5925 through 2032. The $0.4061 average target implies a +66% move from current prices. That is up +10% on the projected 2031 average. Momentum favours further upside here.
The IGC price prediction for 2033 points to an average of $0.4371 (low $0.3188, high $0.6474) — a potential gain of +78% on today's $0.2451. Buyers look set to stay in control over this stretch.
In 2034, IGC is projected to trade between $0.3659 and $0.7631, averaging $0.508 — a potential gain of +107% from today's $0.2451. That is up +16% on the projected 2033 average. Momentum favours further upside here.
IGC Pharma, Inc.'s 2035 outlook centres on $0.5611, within a $0.3993 to $0.8541 range. That is up +10% on the projected 2034 average. That marks a +129% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IGC could reach as high as $1.19, with a base case around $0.7413 and support toward $0.4996 — roughly +202% from $0.2451. Momentum favours further upside here.
Expect IGC to range from $0.8273 to $2.35 through 2050. The $1.35 average target implies a +449% move from current prices. That is up +82% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IGC today (≈ 4,079.96736 IGC) could be worth
$5,489.48
+$4,489.48 (+449%) by 2050 · US Dollar
Based on the average projected IGC price of $1.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IGCwould be worth at today's price.
$1,000 invested in IGC on Jul 31, 2025 (≈ 2,777.777667 IGC) would be worth
$680.83
-$319.17 (-31.9%) today · 0.68× · US Dollar
Based on a IGC entry price of $0.36 vs. today's $0.2451.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.26 | $942.69 | -5.7% |
| 1 month ago | $0.27 | $907.78 | -9.2% |
| 3 months ago | $0.33 | $742.73 | -25.7% |
| 6 months ago | $0.27 | $907.78 | -9.2% |
| 1 year ago | $0.36 | $680.83 | -31.9% |
| All time (5.0y) ago | $1.79 | $136.93 | -86.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IGC forecast.
Our base-case forecast reaches $0.49 around 2034.
Implied market cap at $0.49: $51.14M
These are multi-year forecasts anchored in the following year-by-year outlook. The 2026 forecast has min $0.24, avg $0.24, max $0.3022 with ROI 0 and sentiment NEUTRAL.
From 2027 onward, the average price is projected to rise from $0.2972 (2027) to $0.3535 (2030) with increasing ROIs (23.8 in 2027; 47.3 in 2030) and a bullish sentiment. The forecast continues to improve through 2031–2033, with avg prices of $0.3598 (2031), $0.397 (2032), and $0.4233 (2033), and ROIs of 49.9, 65.4, and 76.4 respectively.
By 2034, the average price is forecast at $0.4913 with ROI 104.7 and bullish sentiment, rising to $0.5476 (2035) with ROI 128.2. The trajectory extends into 2040 with an average of $0.716 and ROI 198.3, and into 2050 with an average of $1.30 and ROI 443.2. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows min $0.2695, avg $0.3535, max $0.497, ROI 47.3, sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with averages rising to $0.2972 in 2027 and to $1.30 in 2050, with ROIs advancing to 23.8 (2027) and 443.2 (2050). The 2026 outlook is $0.24 average with ROI 0 and RSI currently at 20. These are estimates, not guarantees.
Yes. The max forecast reaches $0.5783 in 2032 and $0.626 in 2033, indicating the potential to surpass $0.50 in those years.
Current price is $0.24 and market cap is $25.05M.
For 2026, min $0.24, avg $0.24, max $0.3022, ROI 0, sentiment NEUTRAL.
IGC Pharma, Inc. Community Discussion
0Share your IGC Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.